ESMO® 2026 Highlights: Presenter Vignettes
Videos
Day 1
Dana-Farber Cancer Institute
Retrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A Phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) in the post-CDK4/6 inhibitor (i) setting
Dana-Farber Cancer Institute
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
Hospital Moinhos de Vento
Patient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)
University of Eastern Piedmont
18F-FES PET–defined whole-body ER heterogeneity identifies endocrine responsiveness and predicts survival in ER+/HER2− Metastatic Breast Cancer (MBC): results of a prospective international clinical trial.
Johns Hopkins University
A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer
Japanese Foundation for Cancer Research
Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1
Complejo Hospitalario Universitario Insular - Materno Infantil
Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEYNOTE-B15 study
Memorial Sloan Kettering Cancer Center
Safety and Efficacy of Ixotatug Vedotin (TORL-1-23), a Claudin 6-Targeted ADC, as Monotherapy in Germ Cell Tumors (GCT)
Weill Cornell Medicine
Pembrolizumab or placebo plus concurrent definitive chemoradiotherapy in esophageal and gastroesophageal junction (GEJ) cancer: the Phase 3 randomized KEYNOTE-975 study
National Cancer Center Hospital East
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study
University of Western Australia
A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for HER-2 Negative and Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC): Overall Survival Results of the CCTG/BCT MA.40/FINER Study (NCT04650581)
There is no available videos for this selection! Reset filters
Day 2
Arthur JE Child Comprehensive Cancer Centre
Final analysis of the phase 3 LITESPARK-011 study: belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy
Sorbonne Université
Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study
Emory University School of Medicine
Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
Centre Léon Bérard
Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC with PD-L1 ≥50%: PERSEE phase 3 trial (GFPC 01-2020)
University of Naples Federico II
Final analysis of the GIM3 FATA trial: treatment schedule and three aromatase inhibitors (AIs) comparison in postmenopausal HR-positive (HR+) early breast cancer (eBC)
The Netherlands Cancer Institute
Three-year distant metastasis-free survival of the phase 3 NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma
UCL Cancer Institute
Transcriptome classifier risk stratification and intensification with androgen receptor pathways inhibitors (ARPI) for clinically very high risk prostate cancer (PCa)
CHU Grenoble Alpes
Analysis of the phase 2 part of IFCT-2103 DIAL phase 2-3 randomized trial, comparing continuation pembrolizumab (± pemetrexed) up to 2 years versus observation (± pemetrexed), in patients with metastatic Non-Small Cell Lung Cancer (mNSCLC) with disease control (DC) at 6 months
Sarah Cannon Research Institute
Patritumab Deruxtecan (HER3-DXd) in Melanoma After Anti-PD-(L)1 Therapy: Primary Analysis From HERTHENA-PanTumor01
Hôpital Foch
IROCAS: A randomized phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III (T4 and/or N2) colon cancer.
The Catholic University of Korea
Compression therapy using normal-sized surgical gloves for prevention of paclitaxel-induced peripheral neuropathy in breast cancer: results from the multicenter randomized AIUR trial
Leeds Institute of Medical Research
Omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) versus placebo after resection of colorectal cancer liver metastases (EMT2): A multicentre, double-blind, randomised phase 3 trial
UCLA Health
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the Ph3 RASolute 302 study.
Yonsei University College of Medicine
A global phase 2, open-label trial of pumitamig (PD-L1 × VEGF-A bsAb) + docetaxel post-chemoimmunotherapy in mNSCLC: first data from ROSETTA Lung-107
Klinikum Esslingen
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and gallbladder carcinoma (ACTICCA-1 trial)
University Cancer Center Hamburg
Updated results from the phase 1b/2 KEYNOTE-365 cohort I: pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
Ankara Yıldırım Beyazıt University
Calderasib (MK-1084), alone or in combination, for KRAS G12C-mutant metastatic non-small cell lung cancer (mNSCLC)
UOC Oncologia Medica
PErioperative PEmbrolizumab (P) plus metastasis-directed therapy (MDT) versus MDT alone in patients (pts) with oligometastatic renal cell carcinoma (omRCC): the randomized phase II PE-PE trial.
Peter MacCallum Cancer Centre
C-POST phase 3 trial of adjuvant (adj) cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC): Updated overall survival (OS) and outcomes from circulating tumour DNA (ctDNA) analyses
National Cancer Center Hospital East
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): second interim analysis (IA) from HERIZON-GEA-01
Sunnybrook Odette Cancer Centre
Patient Reported Quality of Life (QoL) for Docetaxel (Doc) vs Lutetium177-617-PSMA (LuP) for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from the Canadian Cancer Trials Group (CCTG) PR21 Trial
Aichi Cancer Center Hospital
Biweekly versus conventional trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer: the pragmatic phase 3 PRABITAS trial
There is no available videos for this selection! Reset filters
Day 3
University of Barcelona
Phase 3 LEAP-012 Study of Lenvatinib + Pembrolizumab vs Dual Placebo With Transarterial Chemoembolization (TACE) for Unresectable Non-metastatic Hepatocellular Carcinoma: Long-term OS Results
Hospital Universitario 12 de Octubre
2074RO
Enfortumab Vedotin (EV) plus Pembrolizumab (P) for Refractory Advanced Melanoma: Primary Results from the PLUG-IN GEM 2301 Trial
2075RO
Phase 1 dose expansion of a tetravalent CD137/PD-L1 bispecific antibody (FS222) in PD-1 inhibitor- resistant melanoma patients.
CHA Bundang Medical Center
Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) Monotherapy: First Disclosure of Dose Optimization (DO) and Dose Escalation (DE) Update in Advanced Hepatocellular Carcinoma (HCC)
Nagoya City University
Ultra-sensitive MRD Assessment in Long-term Complete Responders to Anti-HER2 Therapy in HER2-positive Metastatic Breast Cancer: Initial Results from HER2-CR Study
Erasmus MC
Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO)
Moffitt Cancer Center
Radiation Therapy Followed by Intrathecal (IT) Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Metastasis: Results from a Phase II Multi-Institutional Study, (INSPIRE-LM)
National Cancer Institute Regina Elena
Results of a multicenter, phase II, open-label, randomized trial evaluating OSE2101 plus docetaxel or OSE2101 plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer (NSCLC) progressing after first-line chemo-immunotherapy
UC Davis Comprehensive Cancer Center
Randomized trial of serplulimab or atezolizumab plus chemotherapy in USA patients with extensive-stage small cell lung cancer (ASTRIDE)
Memorial Sloan Kettering Cancer Center
Clinical Complete Response With Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer (LARC): First Results From the Global Registrational AZUR-1 Trial
University Hospital Essen
STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
Fudan University Shanghai Cancer Center
Safety and efficacy of SYS6043, a Novel B7-H3–Targeting Antibody-Drug Conjugate, in Patients with Advanced breast cancer
MD Anderson Cancer Center
Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
Sarah Cannon Research Institute
Safety and efficacy of JNJ-6143, a first-in-class oral AR-targeted RIPTAC™ at the optimal dose for further development in patients with mCRPC/mAPMR, including high-risk molecular features
IOV-IRCCS
Final overall survival results from CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab or chemotherapy in MSI-H/dMMR metastatic colorectal cancer
McGill University
Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)
MD Anderson Cancer Center
First-line (1L) Olomorasib + Chemoimmunotherapy (Chemo-IO) in KRAS G12C-Mutant NSCLC: Updated Results from the LOXO-RAS-20001 and SUNRAY-01 Trials
There is no available videos for this selection! Reset filters